phosphoinositide interacting regulator of transient receptor potential channelsGenealiases: []
Q-omics provides the consensus-scored PIRT profile across patient tissues and cancer cell-line models. PIRT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PIRT is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, PIRT RNA expression shows 10,298 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight BLCA, COAD, and LAML as cancer lineages where PIRT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIRT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIRT survival associations across molecular data types. PIRT RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIRT RNA expression–survival associations across cancer types. High PIRT expression shows unfavorable associations in LGG, CESC, THCA and LUAD, but favorable associations in BLCA and LAML. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify BLCA as the clearest survival context for PIRT RNA expression.
This table summarizes PIRT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PIRT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIRT shows lower tumor expression in COAD, KICH, READ, HNSC, STAD and BLCA. The COAD box plot shows higher PIRT RNA expression in normal versus tumor tissue (log2 FC = −1.753, t-test p < 0.001).
This table shows molecular features associated with PIRT in patient tissues and cancer cell lines. In patient samples, PIRT shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, PIRT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
